PortfoliosLab logo
AVAH vs. HCAT
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Correlation

The correlation between AVAH and HCAT is 0.20, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.


Performance

AVAH vs. HCAT - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Aveanna Healthcare Holdings Inc. (AVAH) and Health Catalyst, Inc. (HCAT). The values are adjusted to include any dividend payments, if applicable.

Loading data...

Key characteristics

Daily Std Dev

AVAH:

114.12%

HCAT:

54.05%

Max Drawdown

AVAH:

-1.82%

HCAT:

-2.46%

Current Drawdown

AVAH:

-1.82%

HCAT:

-1.20%

Fundamentals

Market Cap

AVAH:

$1.05B

HCAT:

$287.40M

EPS

AVAH:

$0.03

HCAT:

-$1.15

PS Ratio

AVAH:

0.50

HCAT:

0.92

PB Ratio

AVAH:

1.17

HCAT:

0.76

Total Revenue (TTM)

AVAH:

$1.53B

HCAT:

$311.47M

Gross Profit (TTM)

AVAH:

$486.86M

HCAT:

$128.83M

EBITDA (TTM)

AVAH:

$142.56M

HCAT:

-$22.50M

Returns By Period


AVAH

YTD

N/A

1M

N/A

6M

N/A

1Y

N/A

5Y*

N/A

10Y*

N/A

HCAT

YTD

N/A

1M

N/A

6M

N/A

1Y

N/A

5Y*

N/A

10Y*

N/A

*Annualized

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Risk-Adjusted Performance

AVAH vs. HCAT — Risk-Adjusted Performance Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

AVAH
The Risk-Adjusted Performance Rank of AVAH is 9191
Overall Rank
The Sharpe Ratio Rank of AVAH is 9090
Sharpe Ratio Rank
The Sortino Ratio Rank of AVAH is 9292
Sortino Ratio Rank
The Omega Ratio Rank of AVAH is 8888
Omega Ratio Rank
The Calmar Ratio Rank of AVAH is 9090
Calmar Ratio Rank
The Martin Ratio Rank of AVAH is 9393
Martin Ratio Rank

HCAT
The Risk-Adjusted Performance Rank of HCAT is 2020
Overall Rank
The Sharpe Ratio Rank of HCAT is 2121
Sharpe Ratio Rank
The Sortino Ratio Rank of HCAT is 2121
Sortino Ratio Rank
The Omega Ratio Rank of HCAT is 2222
Omega Ratio Rank
The Calmar Ratio Rank of HCAT is 2525
Calmar Ratio Rank
The Martin Ratio Rank of HCAT is 1212
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

AVAH vs. HCAT - Risk-Adjusted Performance Comparison

This table presents a comparison of risk-adjusted performance metrics for Aveanna Healthcare Holdings Inc. (AVAH) and Health Catalyst, Inc. (HCAT). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.



Loading data...

Dividends

AVAH vs. HCAT - Dividend Comparison

Neither AVAH nor HCAT has paid dividends to shareholders.


Tickers have no history of dividend payments

Drawdowns

AVAH vs. HCAT - Drawdown Comparison

The maximum AVAH drawdown since its inception was -1.82%, smaller than the maximum HCAT drawdown of -2.46%. Use the drawdown chart below to compare losses from any high point for AVAH and HCAT. For additional features, visit the drawdowns tool.


Loading data...

Volatility

AVAH vs. HCAT - Volatility Comparison


Loading data...

Financials

AVAH vs. HCAT - Financials Comparison

This section allows you to compare key financial metrics between Aveanna Healthcare Holdings Inc. and Health Catalyst, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


0.00100.00M200.00M300.00M400.00M500.00M20212022202320242025
519.87M
79.61M
(AVAH) Total Revenue
(HCAT) Total Revenue
Values in USD except per share items

AVAH vs. HCAT - Profitability Comparison

The chart below illustrates the profitability comparison between Aveanna Healthcare Holdings Inc. and Health Catalyst, Inc. over time, highlighting three key metrics: Gross Profit Margin, Operating Margin, and Net Profit Margin.

Gross Margin
Operating Margin
Net Margin
Quarterly
Annual

30.0%35.0%40.0%45.0%50.0%20212022202320242025
33.0%
43.6%
(AVAH) Gross Margin
(HCAT) Gross Margin
AVAH - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on May 2025, Aveanna Healthcare Holdings Inc. reported a gross profit of 171.72M and revenue of 519.87M. Therefore, the gross margin over that period was 33.0%.

HCAT - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on May 2025, Health Catalyst, Inc. reported a gross profit of 34.69M and revenue of 79.61M. Therefore, the gross margin over that period was 43.6%.

AVAH - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on May 2025, Aveanna Healthcare Holdings Inc. reported an operating income of 45.77M and revenue of 519.87M, resulting in an operating margin of 8.8%.

HCAT - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on May 2025, Health Catalyst, Inc. reported an operating income of -17.50M and revenue of 79.61M, resulting in an operating margin of -22.0%.

AVAH - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on May 2025, Aveanna Healthcare Holdings Inc. reported a net income of 29.18M and revenue of 519.87M, resulting in a net margin of 5.6%.

HCAT - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on May 2025, Health Catalyst, Inc. reported a net income of -20.67M and revenue of 79.61M, resulting in a net margin of -26.0%.